Profil
Joan Smith is the founder and Head-Technical of Meliora Therapeutics, Inc. which is founded in 2020.
He is also an Advisor at Surface Ventures since 2020.
Mr. Smith completed his undergraduate degree from Massachusetts Institute of Technology in 2013.
Postes actifs de Joan Smith
| Sociétés | Poste | Début |
|---|---|---|
Surface Ventures
 Surface Ventures Investment ManagersFinance Surface Ventures (Surface Ventures) is a venture capital firm founded in 2020 by Gyan Kapur and Dimitri Boguslavsky. The firm is headquartered in New York. | Consultant / Advisor | 01/09/2020 |
Meliora Therapeutics, Inc.
 Meliora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Meliora Therapeutics, Inc. is an American company that is revolutionizing cancer drug development by utilizing genomics and advanced computational methods as key components of their product development process. The company is based in California. The company has created "molecular fingerprints" for thousands of compounds to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (moa) pairs. This unique discovery engine has the potential for high clinical success. Meliora Therapeutics was founded in 2021 by Jason Sheltzer, Joan Smith, and David Li. David Li has been the CEO since 2021. | Fondateur | 01/02/2020 |
Formation de Joan Smith
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Surface Ventures
Surface Ventures Investment ManagersFinance Surface Ventures (Surface Ventures) is a venture capital firm founded in 2020 by Gyan Kapur and Dimitri Boguslavsky. The firm is headquartered in New York. | Finance |
Meliora Therapeutics, Inc.
Meliora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Meliora Therapeutics, Inc. is an American company that is revolutionizing cancer drug development by utilizing genomics and advanced computational methods as key components of their product development process. The company is based in California. The company has created "molecular fingerprints" for thousands of compounds to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (moa) pairs. This unique discovery engine has the potential for high clinical success. Meliora Therapeutics was founded in 2021 by Jason Sheltzer, Joan Smith, and David Li. David Li has been the CEO since 2021. | Commercial Services |
